Author:
Martin Claire S.,Cooper Mark S.,Hardy Rowan S.
Abstract
The role of tissue specific metabolism of endogenous glucocorticoids (GCs) in the pathogenesis of human disease has been a field of intense interest over the last 20 years, fuelling clinical trials of metabolism inhibitors in the treatment of an array of metabolic diseases. Localised pre-receptor metabolism of endogenous and therapeutic GCs by the 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes (which interconvert endogenous GCs between their inactive and active forms) are increasingly recognised as being critical in mediating both their positive and negative actions on bone homeostasis. In this review we explore the roles of endogenous and therapeutic GC metabolism by the 11β-HSD enzymes in the context of bone metabolism and bone cell function, and consider future strategies aimed at modulating this system in order to manage and treat various bone diseases.
Subject
Endocrinology, Diabetes and Metabolism
Reference126 articles.
1. Effects of an 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, MK-0916, in Patients With Type 2 Diabetes Mellitus and Metabolic Syndrome;Feig;Diabetes Obes Metab,2011
2. Safety, Efficacy and Weight Effect of Two 11beta-HSD1 Inhibitors in Metformin-Treated Patients With Type 2 Diabetes;Heise;Diabetes Obes Metab,2014
3. Efficacy and Safety Evaluation of HSD-1 Inhibitor ABT-384 in Alzheimer’s Disease;Marek;Alzheimer’s Dementia: J Alzheimer’s Assoc,2014
4. The 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy;Rosenstock;Diabetes Care,2010
5. Oral Administration of the 11beta-Hydroxysteroid-Dehydrogenase Type 1 Inhibitor RO5093151 to Patients With Glaucoma: An Adaptive, Randomised, Placebo-Controlled Clinical Study;Schwab;BMJ Open Ophthalmol,2017
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献